Micrococcin P1

Micrococcin P1 is a multicyclic peptide with activity against a broad range of Gram positive bacteria,

including vancomycin-resistant enterococci (VRE), meticillin-resistant Staphylococcus pseudintermedius (MRSP), meticillin-resistant Staphylococcus aureus (MRSA), Listeria monocytogenes, Clostridium difficile

as well as M. tuberculosis, P. falciparum etc



0,5 mg

450 €

1 mg

800 €

5 mg

3000 €

Name                           Micrococcin P1
Class                             Thiopeptide
Sequence                    SCTTCVCTCSCCTT
PubChem                   CID 3051328
Molecular Formula   C48H49N13O9S6
Molecular Weight     1144.4
IUPAC Name              2-[2-[26-ethylidene-12,29-bis(1-hydroxyethyl)-14,21,28,31-                                                         tetraoxo-19-propan-2-yl-10,17,24,34-tetrathia 6,13,20,27,                                                             30,35,36,37,38-nonazahexacyclo [,11.115,18.122,                                                                 25.02,7] octatriaconta-1(35),2(7),3,5,8,11(38),15,18(37),                                                                   22,25(36),32-undecaen-5-yl]-1,3-thiazol-4-yl]-N-[1-(2-                                                                 hydroxypropylamino) -1-oxobut-2-en-2-yl]-1,3-thiazole

Purity                            > = 95%
Producer Organism  Bacillus pumilus
Expected target         Gram-positive bacteria, including, MRSA, VRE, listeria, clostridia                                           etc. M. tuberculosis P. falciparum


  1. Ovchinnikov, K. V., Kranjec, C., Thorstensen, T., Carlsen, H., & Diep, D. B. (2022). Bacteriocins Revitalize Non-Effective Penicillin G to Overcome Methicillin-Resistant Staphylococcus pseudintermedius. Antibiotics, 11(12). https://doi.org/10.3390/antibiotics11121691
  2. Ovchinnikov, K. V., Kranjec, C., Telke, A., Kjos, M., Thorstensen, T., Scherer, S., Carlsen, H., & Diep, D. B. (2021). A Strong Synergy Between the Thiopeptide Bacteriocin Micrococcin P1 and Rifampicin Against MRSA in a Murine Skin Infection Model. Frontiers in Immunology, 12(July), 1–13. https://doi.org/10.3389/fimmu.2021.676534

  3. Ovchinnikov, K. V., Kranjec, C., Thorstensen, T., Carlsen, H., & Diep, D. B. (2020). Successful Development of Bacteriocins into Therapeutic Formulation for Treatment of MRSA Skin Infection in a Murine Model. Antimicrobial Agents and Chemotherapy, 64(12), 1–13. https://doi.org/10.1128/AAC.00829-20